Navigation Links
Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile
Date:2/17/2009

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include product development, product potential projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMEA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives as well as those discussed or identified in the public filings with the SEC and the AMF
'/>"/>

SOURCE Sanofi Pasteur
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sanofi Aventis: People With Type 2 Diabetes Treated With LANTUS(R) and APIDRA(R) Achieved Greater Reductions in A1C Than Those Treated With Pre-mixed Insulin
2. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
3. Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US
4. Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile
5. Sanofi Pasteur Initiates Phase II Trial of Cell Culture-Based Seasonal Influenza Vaccine
6. Sanofi Pasteur Receives FDA Approval of Meningococcal Vaccine for Children
7. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
8. Clinical Update - Debio 9902 SR (ZT-1) for Alzheimer Patients Debiopharm Starts Tablet Formulations Bridging Study under IND
9. Presbyterian Hospital Dallas Starts Advanced Breast-Cancer Risk-Assessment Program
10. U.S. NCI Starts Enrolment in Phase 2 Systemic Melanoma Clinical Trial with REOLYSIN(R)
11. BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... PharmaTech (Cayman) Inc. (NYSE: WX ), a ... the pharmaceutical, biotechnology, and medical device industries, with operations ... financial results for the fourth quarter and full year ... Net Revenues Increased 21.3% Year Over Year to $190.6 ... Year Over Year to $140.5 Million , Manufacturing ...
(Date:3/5/2015)... NEW YORK , March 5, 2015 /PRNewswire/ ... evolving set of regulations, Ethics & Compliance professionals ... according to a new survey issued today by ... services and education. An overwhelming majority of respondents ... far the most important component of E&C training ...
(Date:3/5/2015)... --  ndd Medical Technologies , a leader in innovative ... technology, announced that its EasyOne Pro® was used at ... Pulmonary Fibrosis Support Group. The clinic targeted patients with ... well as those suspected of having ILD or PF. ... square inches, EasyOne Pro provides accurate respiratory test results ...
Breaking Medicine Technology:WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 2WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 3WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 4WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 5WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 6WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 7WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 8WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 9WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 10WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 11WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 12WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 13WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 14WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 15WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 16WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 17WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 18WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 19WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 20WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 21WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 22Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 2Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 3ndd Medical Technologies' Mobile Pulmonary Function Testing Helps Combat Pulmonary Fibrosis 2ndd Medical Technologies' Mobile Pulmonary Function Testing Helps Combat Pulmonary Fibrosis 3
... and Phase 1b Combination Clinical Trials ... Anti-Leukemic Activity, SOUTH SAN FRANCISCO, Calif., June 16 ... two,clinical trials of the company,s lead drug candidate, voreloxin (formerly,SNS-595), ... when,used as a single agent in relapsed or refractory patients ...
... Patients Not Optimally Controlled with, Levodopa ... Hours Per Day, RESEARCH TRIANGLE PARK, N.C., ... announced the approval of Requip(R),XL(TM) (ropinirole extended-release tablets) ... and symptoms of idiopathic Parkinson,s disease. Requip XL ...
Cached Medicine Technology:Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association 2Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association 3Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association 4Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association 5Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association 6U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinson's Disease 2U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinson's Disease 3U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinson's Disease 4U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinson's Disease 5
(Date:3/5/2015)... In 2014, the FDA approved 44 drugs, with ... scoring 4 drug approvals in the USA. The infectious ... drug products, followed by oncology therapy with 18% of ... CDK inhibitors keep on attracting large-cap pharmacos. Nivolumab and ... metastatic melanoma, and at present, they are being investigated ...
(Date:3/5/2015)... 2015 AxoGen, Inc. (NASDAQ: AXGN) ... peripheral nerve repair market, reported record revenue of $4.79 ... compared to $2.98 million in the year-ago fourth quarter ... , “Our strong fourth quarter revenue growth reflects ... products which is driving increased surgeon adoption of our ...
(Date:3/5/2015)... March 05, 2015 HomeCEUConnection.com ... March with extra savings on their nutrition ... of health and nutrition, HomeCEUConnection.com is offering ... the promo code, NUTRITION2015 . , ... , HomeCEUConnection.com provides high-quality continuing education ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 TCS Healthcare ... solutions for the population health management arena, is pleased ... case management software, ACUITY Advanced Care™ (ACUITY) version 7.20. ... improved performance and the advantages of automation. , The ... ET, will be led by Jeff Frater, RN, BSN, ...
(Date:3/5/2015)... 05, 2015 University of Western ... in 1904, has launched a new center of ... changes. The Northwest Center for Lifestyle and Functional ... community outreach, and conduct research in the areas ... and nutrition. The center will target efforts on ...
Breaking Medicine News(10 mins):Health News:World Pharma Business and Large-Cap Companies Discussed by MP Advisors in In-demand Study Available at MarketPublishers.com 2Health News:World Pharma Business and Large-Cap Companies Discussed by MP Advisors in In-demand Study Available at MarketPublishers.com 3Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 2Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 3Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 4Health News:HomeCEUConnection.com Offers Nutrition CEUs this March to Celebrate Nutrition Month 2Health News:Complimentary Webinar to Explore Enhanced Version of Premier Case Management Software 2Health News:Complimentary Webinar to Explore Enhanced Version of Premier Case Management Software 3Health News:University of Western States Launches Northwest Center for Lifestyle and Functional Medicine 2
... living only days longer despite treatment advances, study finds , ... preterm babies in England have not improved over the past ... active treatment, a new study shows. , Researchers analyzed the ... of pregnancy, which is considered to be at the "margins ...
... dismiss need for long-term antibiotic therapy, but opponents call ... News) -- After more than a year of study, ... of America has decided that controversial guidelines for the ... be changed. , The guidelines, first adopted in 2006, ...
... ... pre-event for the American Cancer Society’s highly anticipated “Starry Night Gala” that will occur ... ... 21, 2010 -- “An Evening of Hope” is the official pre-event for the ...
... ... , ... prevention and management has come a long way in the last few decades. Advent of ... evil monster., , ,We are excited though to tell about the latest technique Dr. Khanna ...
... didn,t make a difference, study finds , THURSDAY, April ... to wait longer for diagnosis and treatment than white ... finds. , Researchers from the GW Cancer Institute looked ... 1997 and 2009 at seven hospitals and clinics in ...
... Employees hold fundraiser ... ... the recovery efforts in Haiti, AthletiCo Physical and Occupational Therapy held a special jean ... from the event is being donated to Partners in Health Stand with Haiti . ...
Cached Medicine News:Health News:Youngest Preemies' Survival Rate Unchanged 2Health News:Review Panel Leaves Controversial Lyme Disease Guidelines Unchanged 2Health News:Review Panel Leaves Controversial Lyme Disease Guidelines Unchanged 3Health News:Review Panel Leaves Controversial Lyme Disease Guidelines Unchanged 4Health News:“An Evening Of Hope” - Tonight is the Official Pre-Event for this Year's American Cancer Society Starry Night Gala 2Health News:Glued graft for Pterygium Yield Better Cosmetic Results 2Health News:Glued graft for Pterygium Yield Better Cosmetic Results 3Health News:Black Women Wait Longer for Breast Cancer Diagnosis, Treatment 2Health News:AthletiCo Physical and Occupational Therapy Supports Partners in Health Stand with Haiti 2
... Technologies, The UroMax Ultra ia designed ... high pressure and low profile., Refolding ... a remarkably strong material that is ... materials., Non-Compliant Balloons, A compliant balloon ...
... Fr Diameter with Two Large Working Channels; ... MICRO-6 Semi-Rigid Ureteroscope is the smallest ureteroscope ... and therapeutic procedures. The ACMI MICRO-6 Ureteroscope ... procedures with minimal or no dilation or ...
... is a self-dilating, semi-rigid autoclavable operating ureteroscope ... image bundle for an enhanced, clear image. ... to "0" diopters. The direction of view ... passage. The straight access operating channel is ...
... tip diameter of only 6.9Fr (2.3mm) ... range of 180 for and easy ... observation, a new optical system has ... (3.9mm) sheath dilator, 0.035" guidewire compatible, ...
Medicine Products: